Xencor, Inc.

Xencor, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Xencor, Inc. is not very popular among insiders. Xencor, Inc. is a mediocre stock to choose.
Log in to see more information.
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat seve...
XNCR Fundamental Data by TradingView

News

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares

Business Wire Xencor, Inc. (Xencor) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the closing...\n more…

Xencor (XNCR) Shares Cross Above 200 DMA
Xencor (XNCR) Shares Cross Above 200 DMA

Market News Video In trading on Wednesday, shares of Xencor, Inc (XNCR) crossed above their 200 day moving average of 20.50, changing hands as high as 21.21 per share. Xencor, Inc shares are currently...\n more…

Xencor 6.64M share Spot Secondary priced at $18.00
Xencor 6.64M share Spot Secondary priced at $18.00

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Xencor stock falls after it prices $175M public offering
Xencor stock falls after it prices $175M public offering

Seeking Alpha - Healthcare Xencor stock falls after it prices $175M public offering...\n more…

Xencor Announces Pricing of $175 Million Public Offering of Common Stock
Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Business Wire Xencor, Inc. (Xencor) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the pricing...\n more…

Wedbush Reiterates Outperform Rating for Xencor (NASDAQ:XNCR)
Wedbush Reiterates Outperform Rating for Xencor (NASDAQ:XNCR)

Ticker Report Xencor (NASDAQ:XNCR - Get Free Report)s stock had its "outperform" rating reiterated by investment analysts at Wedbush in a research report issued on Monday, RTT News reports. They presently...\n more…